LEADER 03053nam  2200637Ia 450 
001 996320245903316
005 20230725024605.0
010   $a1-282-76081-5
010   $a9786612760815
010   $a92-4-068535-9
035   $a(CKB)2670000000037978
035   $a(EBL)579104
035   $a(OCoLC)662259096
035   $a(SSID)ssj0000430069
035   $a(PQKBManifestationID)11301594
035   $a(PQKBTitleCode)TC0000430069
035   $a(PQKBWorkID)10453598
035   $a(PQKB)10204619
035   $a(MiAaPQ)EBC579104
035   $a(Au-PeEL)EBL579104
035   $a(CaPaEBR)ebr10411821
035   $a(CaONFJC)MIL276081
035   $a(EXLCZ)992670000000037978
100   $a20100802d2010      uf             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aTreatment of tuberculosis$b[electronic resource] $eguidelines
205   $a4th ed.
210   $aGeneva $cWorld Health Organization$d2010
215   $a1 online resource (159 p.)
300   $aPrevious editions had different title : "Treatment of tuberculosis : guidelines for national programmes".
300   $a"WHO/HTM/TB/2009.420."
300   $a"World Health Organization, Stop TB Dept."
311   $a92-4-154783-9 
320   $aIncludes bibliographical references.
327   $aCOVER; COPYRIGHT; Contents; Abbreviations; Acknowledgements; Foreword; Executive summary; Introduction; Case definitions; Standard treatment regimens; Monitoring during treatment; Co-management of HIV and active TB disease; Supervision and patient support; Treatment of drug-resistant tuberculosis; Treatment of extrapulmonary TB and of TB in special situations; Annexes; Essential first-line antituberculosis drugs; Summary of evidence and considerations underlying the recommendations; TB treatment outcomes; Suggestions for future research
330   $aThe World Health Organization's Stop TB Department has prepared this fourth edition of Treatment of Tuberculosis: Guidelines, adhering fully to the new WHO process for evidence-based guidelines. Several important recommendations are being promoted in this new edition. First, the recommendation to discontinue the regimen based on just 2 months of rifampicin (2HRZE/6HE) and change to the regimen based on a full 6 months of rifampicin (2HRZE/4HR) will reduce the number of relapses and failures. This will alleviate patient suffering resulting from a second episode of tuberculosis (TB) and conserve
606   $aAntitubercular agents
606   $aTuberculosis$xChemotherapy
606   $aPatient compliance
615  0$aAntitubercular agents.
615  0$aTuberculosis$xChemotherapy.
615  0$aPatient compliance.
676   $a616.995061
712 02$aWorld Health Organization.
712 02$aStop TB Initiative (World Health Organization)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a996320245903316
996   $aTreatment of tuberculosis$92121661
997   $aUNISA